Skip to main content
Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.
Partnership
1 min read

Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.

Auxilium Biotechnologies
Auxilium Biotechnologies

Hardware

Originally reported by 3D Printing Industry

Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit. Building on successful ISS trials of perfusable vascular systems, this agreement establishes a permanent workflow for complex tissue engineering and implantable devices. By leveraging microgravity to bypass 1g structural limits, the partnership is industrializing regenerative medicine for Earth-based clinical use. This move transitions orbital 3D bioprinting into a core pillar of the emerging space life sciences economy. 🚀🧬🛰️ #3DPrinting #Bioprinting #SpaceEconomy #MedTech

Explore Auxilium BiotechnologiesRead Original

How This Connects

6 related events
  1. Same pattern

    Cyfuse and NSK announce the development of a new bio-3D printer designed for the commercial production of regenerative medicine and 3D cell products.

  2. Same pattern

    EPFL researchers developed a room-temperature 3D printing process using enzyme-driven mineralization to create bone scaffolds that become load-bearing within 7 days.

  3. This article

    Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.

  4. Same pattern

    PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.

  5. Same pattern

    Carnegie Mellon University secured a 28.5 million dollar ARPA-H award for the LIVE project, developing 3D-printed human liver patches.

  6. Same pattern

    Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.

  7. Same pattern

    Nanochon secured $4.1M in funding to launch first-in-human trials for its 3D-printed knee implant.